NRG Oncology Network Group Operations Center - BIQSFP

NRG 肿瘤网络集团运营中心 - BIQSFP

• 批准号: 10453850
• 负责人: ROBERT S. MANNEL
• 金额: $ 30.25万
• 依托单位: NRG ONCOLOGY FOUNDATION, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-17 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10453850
• 关键词: Adult; African; Area; Awareness; Brain Neoplasms; Breast; Cancer Patient; Cancer Therapy Evaluation Program; Clinical Research; Clinical Trials; Development; Disease; Enrollment; Ensure; Gender; Goals; Gynecologic; Head and Neck Cancer; Hispanics; International; Latino; Lead; Leadership; Locally Advanced Malignant Neoplasm; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Malignant neoplasm of prostate; Malignant neoplasm of urinary bladder; Manuscripts; National Clinical Trials Network; Non-Hematologic Malignancy; Oncology; Patients; Peer Review; Positioning Attribute; Precision medicine trial; Protocols documentation; Publishing; Research; Scientific Advances and Accomplishments; Site; Time; Translational Research; advanced disease; advanced prostate cancer; clinically relevant; cohort; design; improved; interest; malignant breast neoplasm; member; multidisciplinary; oncology trial; operation; patient population; sarcoma

NRG Overall Component Abstract NRG Oncology (NRG) has made significant progress toward its goal of improving the lives of adults with certain non-hematologic malignancies through its clinical and translational research efforts. NRG's defined patient populations of interest - those with gender-specific malignancies and/or those with localized or locally advanced disease, are unique within the NCTN, constituting a large and relatively under-investigated cohort of cancer patients. Positioned to be the lead NCTN research organization for trials enrolling several patient cohorts, NRG's portfolio focuses on patients with gynecologic cancer, primary or secondary brain tumors, head and neck cancer, or localized or locally advanced prostate cancer as well as breast cancer, lung cancer, gastrointestinal cancer, bladder cancer, or sarcoma. In these and other realms NRG, actively collaborates with other NCTN groups, diligently working to increase awareness of and participation in all NCTN trials. NRG's research accomplishments to date have been extraordinary. There have been 87 CTEP- supported NRG trials open for enrollment during this period, representing 34% of the open NCTN adult trials. For the period March 1, 2014 through August 31, 2017, NRG members entered 10,840 patients onto NRG-led trials, 3,199 patients into trials led by other NCTN network groups, and an additional 1,906 patients onto NCTN Precision Medicine Trials for a total of 15,945 entries. Of the 48,056 total NCTN treatment enrollments, NRG's contribution accounts for 33% of the total entries and represents the largest accrual of any of the five NCTN groups. Of patients enrolled onto NRG trials at U.S. sites, 12.7% were self-identified as of African descent and 8.0% as Latino or Hispanic. There have been 302 NRG peer-reviewed manuscripts published or in press and 365 published abstracts during this period, of which at least 52 contain practice-changing or practice-defining observations. To successfully fulfill its ambitious goal, NRG has seven cancer disease site committees, all with internationally recognized multi-disciplinary leadership and all with strong liaison representatives from NRG's nine scientific core committees. There are four other protocol-generating committees and five administrative committees, all designed to lead and support critical areas of the group's research. NRG is organized such that the necessary operational efficiencies and internal peer review are in order to overcome barriers to conducting a broad portfolio of scientifically important and relevant clinical trials and to ensuring appropriate enrollment to these trials.

NRG整体组件摘要 NRG肿瘤学（NRG）在实现改善患者生活的目标方面取得了重大进展。 通过其临床和转化研究， 努力NRG定义的关注患者人群-性别特异性恶性肿瘤患者 和/或患有局部或局部晚期疾病的患者，在NCTN中是独特的， 构成了一个大的且相对未被充分研究的癌症患者群体。定位成 NRG是NCTN研究组织的领导者，负责招募多个患者队列的试验， 主要针对妇科癌症、原发性或继发性脑肿瘤、头颈部肿瘤 癌症或局部或局部晚期前列腺癌以及乳腺癌，肺癌， 胃肠癌、膀胱癌或肉瘤。在这些和其他领域，NRG积极地 与其他NCTN团体合作，努力工作，以提高认识， 参与所有NCTN试验。 NRG迄今为止的研究成就是非凡的。共87个CTEP- 在此期间开放入组的受支持NRG试验占开放试验的34% NCTN成人试验。2014年3月1日至2017年8月31日期间，NRG成员 10，840名患者进入NRG领导的试验，3，199名患者进入其他NCTN领导的试验 网络组，以及另外1，906名患者参加NCTN精准医学试验， 共有15,945个条目。在48，056例NCTN治疗登记中，NRG的贡献 占总条目的33%，是五个NCTN中最大的一个 组在美国临床试验机构入组NRG试验的患者中，12.7%的患者自认为是 非洲裔和8.0%的拉丁裔或西班牙裔。 已有302篇NRG同行评议的手稿出版或出版，365篇已出版 摘要在此期间，其中至少52个包含实践改变或实践定义 意见。为了成功实现其雄心勃勃的目标，NRG有七个癌症疾病网站 委员会，所有国际公认的多学科领导和所有强大的 NRG的九个科学核心委员会的联络代表。还有另外四 协议制定委员会和五个行政委员会，所有这些委员会都旨在领导和 支持小组研究的关键领域。NRG的组织方式是， 运营效率和内部同行评审是为了克服开展业务的障碍 广泛的科学重要性和相关临床试验组合，并确保适当的 参加这些试验。